Responses to angiotensin II (Ang II) were investigated in anaesthetised CD1 mice. Injections of Ang II caused dose-related increases in systemic arterial pressure that were antagonised by candesartan. Responses to Ang II were not altered by PD 123319. At the lowest dose studied (20 µg/kg i.v.), the inhibitory effects of candesartan were competitive, whereas at the highest dose (100 µg/kg i.v.), the dose-response curve for Ang II was shifted to the right in a non-parallel manner. The inhibitory effects of candesartan were selective and were similar in animals pretreated with enalaprilat to reduce endogenous Ang II production. Pressor responses to Ang II were not altered by propranolol, phentolamine or atropine, but were enhanced by hexamethonium. Increases in total peripheral resistance were inhibited by the AT 1 -receptor antagonist (ARB) but were not altered by AT 2 -receptor, alpha-or beta-receptor antagonists. These results suggest that pressor responses to Ang II are mediated by AT 1 -receptors, are buffered by the baroreceptors, are not modulated by effects on AT 2receptors, and that activation of the sympathetic nervous system plays little role in mediating rapid haemodynamic responses to the peptide in anaesthetised mice.
Introduction
Angiotensin II (Ang II) plays an important role in regulating arterial pressure, sodium, and water balance. 1 Ang II binds with high affinity to AT 1and AT 2 -receptors. [2] [3] [4] Ang II-induced increases in systemic arterial pressure and the release of aldosterone are mediated by AT 1 -receptors, whereas less is known about the role of the AT 2 -receptor in the regulation of cardiovascular function. [2] [3] [4] AT 1receptors are widely distributed, and AT 1 -antagonists are effective in the treatment of hypertension and congestive heart failure. 5 AT 2 -receptors are highly expressed in the foetus and are downregulated with time, suggesting that they are involved in growth and development. 6 A new approach to the study of the role of AT 1 -and AT 2receptors has been the development of models in which AT 1 -and AT 2 -receptors are deleted or over expressed. [7] [8] [9] The results of studies in transgenic mice overexpressing the AT 2 -receptor and in mice in which AT 2 -receptors are knocked out suggest a role for the AT 2 -receptor in the regulation of blood pressure and responses to Ang II. [7] [8] [9] However, the results of pharmacological studies in the anaesthetised cat and rat and in the sodium-depleted rat do not support a role for AT 2 -receptors. [10] [11] [12] [13] [14] In an attempt to characterise acute haemodynamic responses to Ang II and to define the role of AT 1and AT 2 -receptors and the autonomic nervous system in mediating pressor responses to Ang II in the mouse (a species in which less is known), the effects of candesartan and of PD 123319, AT 1 -and AT 2 -receptor antagonists, respectively, and of autonomic blocking agents on increases in systemic arterial pressure and total peripheral resistance in response to Ang II were investigated in anaesthetised CD1 mice.
Materials and methods
Adult CD1 mice (Harlan Sprague-Dawley, Inc., Indianapolis, IN) weighing 20-35 g were anaesthetised with thiobutobarbital sodium (90 mg/kg i.p.; Inactin, BYK-Gulden, Constance, Germany) and ketamine hydrochloride (3 mg/kg i.p.; Ketaset, Fort Dodge Labs, Inc., Fort Dodge, IA). Supplemental doses of thiobutobarbital were given i.p. as needed to maintain a uniform level of anaesthesia. The trachea was cannulated with PE-90 tubing (Intramedic, Clay Adams, Parsippany, NJ), and the mice spontaneously breathed room air enriched with 95% O 2 /5% CO 2 . PE 10 catheters were inserted into an external jugular vein for the i.v. administration of drugs and into a carotid artery for the measurement of systemic arterial pressure. Systemic arterial pressure was measured with a Viggo-Spectramed transducer (Viggo-Spectramed, Oxnard, CA) and was recorded on a Grass model 7 polygraph (Grass Instrument Co, Quincy, MA). Mean pressure was derived by electronic averaging, and heart rate was determined from the interval between arterial pressure pulses using a tachograph (Grass model P44).
Increases in total peripheral resistance induced by i.v. injections of Ang II were evaluated, and cardiac output was measured by the thermodilution technique. 15, 16 A known volume (20 µl plus catheter dead space) of 0.9% NaCl solution at 23°C was injected into the right atrium and changes in blood temperature were measured in the root of the aorta by a cardiac output computer (Cardiotherm 500, Columbus Instruments, Columbus, OH) equipped with a small animal interface. The thermistor microprobe catheter (Columbus Instruments, Fr-1) was inserted into the right carotid artery and advanced to the aortic arch where aortic blood temperature was measured. A catheter placed in the right jugular vein was advanced to the right atrium for rapid bolus administration of the saline injectate. The saline solution was injected with a constant-rate syringe to ensure rapid and repeatable injections of the saline indicator solution. Thermodilution curves, which were inscribed within a 10-12 second period, were recorded on a chart recorder. In these experiments, cardiac output was measured during the control period and when systemic arterial pressure reached its peak value following injection of Ang II at a dose of 1 µg/kg i.v. Total peripheral resistance was calculated by dividing the mean arterial pressure by the cardiac output, and the effects of candesartan, PD 123319, phentolamine, and propranolol were investigated.
Candesartan (AstraZeneca, Mölndal, Sweden) was dissolved in a 1 N Na 2 CO 3 :0.9% NaCl solution (1:20) . PD 123319 (Research Biochemical, Natick, MA) was dissolved in 0.9% NaCl. Candesartan and PD 123319 solutions were made just prior to use and were injected into the external jugular vein. Ang II, acetylcholine chloride, propranolol hydrochloride, bradykinin, norepinephrine hydrochloride, atropine sulfate, hexamethonium bromide, vasopressin (Sigma Chemical Co, St. Louis, MO), enalaprilat (Merck, Rahway, NJ), DEA/NO (Research Biochemical, Inc., Natick, MA), and phentolamine mesylate (CIBA-GEIGY, Summit, NJ) were dissolved in 0.9% NaCl, and the solutions were divided into aliquots and stored frozen in 1 ml plastic tubes. U46619 (Upjohn, Kalamazoo, MI) was dissolved in 100% ethanol at a concentration of 10 mg/ml and was diluted in 0.9% NaCl, and the solutions were divided into aliquots and stored frozen in 1 ml plastic tubes. The aliquots were thawed and used on the day of the experiment. During each experiment, the agonist solutions were kept on crushed ice.
The agonists were administered i.v. in small volumes (10-30 µl) over a period of 10-15 seconds in a random sequence. In experiments in which the effects of antagonists on responses to Ang II were investigated, increases in mean systemic arterial pressure were compared before and 10-20 minutes after administration of the antagonist. Increases or decreases in systemic arterial pressure were expressed as peak change from baseline in mmHg. Changes in cardiac output were expressed in ml/min, and changes in heart rate were expressed as percent change from baseline.
The haemodynamic data were analysed using a one-way analysis of variance (ANOVA) with a Scheffe's post hoc test or a paired t-test. A p-value of less than 0.05 was used as the criterion for statistical significance.
Results
Injections of Ang II, 0.1-3 nmol/kg i.v., in anaesthetised CD1 mice caused dose-related increases in systemic arterial pressure ( Figure 1 ). Ang II was approximately 10-fold more potent than norepinephrine and the thromboxane A 2 in increasing systemic arterial pressure in the mouse, when doses are expressed on a nanomolar basis to take molecular weight into account.
Increases in systemic arterial pressure in response to Ang II (1 µg/kg i.v.) was the same in animals with the thermistor catheter inserted into the carotid artery.
Following administration of the AT 1 -receptor antagonist (ARB), candesartan, at a dose of 20 µg/kg i.v., increases in systemic arterial pressure in response to Ang II were significantly reduced, and the dose-response curve for Ang II was shifted to the right in a parallel manner ( Figure 1 ). However, in two other groups of mice in which the inhibitory effects of candesartan at higher doses of 40 and 100 µg/kg i.v. were investigated, pressor responses to Ang II were markedly reduced or abolished, and the dose-response curves were shifted to the right in a non-parallel manner (Figure 1 ). At the highest dose studied, the candesartan-induced blockade could not be surmounted when doses of Ang II up to 100 nmol/kg i.v. were injected (Figure 1 , lower panel). Although candesartan antagonised pressor responses to Ang II, increases in systemic arterial pressure in response to norepinephrine, U46619, and vasopressin and decreases in systemic arterial pressure in response to acetylcholine, the nitric oxide donor DEA/NO, albuterol, and bradykinin were not altered.
Following administration of PD 123319 (10 and 25 mg/kg i.v.), increases in systemic arterial pressure in response to Ang II were not changed.
PD 123319 did not alter pressor responses to norepinephrine and U46619 or depressor responses to acetylcholine, DEA/NO, or albuterol. The administration of PD 123319 (10 mg/kg i.v.) to mice treated with candesartan (100 µg/kg i.v.) had no effect on the reduction in the pressor response to Ang II caused by candesartan.
In mice pretreated with enalaprilat, 1 mg/kg i.v., to reduce endogenous Ang II production, increases in systemic arterial pressure in response to i.v. injections of Ang II were decreased significantly by candesartan (100 µg/kg i.v.). but were not changed by PD 123319 (25 mg/kg i.v.). Treatment with enalaprilat significantly attenuated the increase in systemic arterial pressure in response to angiotensin I and enhanced the decrease in systemic arterial pressure in response to bradykinin, but did not alter pressor responses to Ang II or to norepinephrine in the mouse.
The effects of phentolamine, propranolol, and atropine on increases in systemic arterial pressure in response to Ang II were also investigated. Following administration of phentolamine, 200 µg/kg i.v., increases in systemic arterial pressure in response to i.v. injections of Ang II were not changed, whereas the pressor response to norepinephrine was significantly reduced (Figure 2 ). Following administration of propranolol, 200 µg/kg i.v., increases in systemic arterial pressure in response to Ang II were not changed,whereas decreases in systemic arterial pressure in response to isoproterenol were significantly reduced ( Figure 2 ). Following administration of atropine, 1 mg/kg i.v., pressor responses to Ang II were not altered, whereas vasodepressor responses to acetylcholine were significantly decreased ( Figure 2) .
The effects of the ganglion-blocker, hexamethonium, on the increase in systemic arterial pressure in response to Ang II were investigated. Following administration of hexamethonium, 5 mg/kg i.v., the increases in systemic arterial pressure in response to Ang II were larger in magnitude and longer in duration as measured by the t 1 / 2 of the vasopressor response ( Figure 2 ).
Ang II-induced increases in systemic arterial pressure were associated with small, but significant, increases in heart rate (Figure 3 ). The peak increase in arterial pressure occurred within 30 seconds of i.v. injection of Ang II, whereas the peak increase in heart rate occurred within 50 seconds after injection. These increases in heart rate were reduced significantly by candesartan (100 µg/kg i.v.), PD 123319 (25 mg/kg i.v.), propranolol (500 µg/kg i.v.), or atropine (1 mg/kg i.v.) ( Figure  3) . The Ang II-induced increases in heart rate were not altered by administration of the alpha-receptor antagonist phentolamine (200 µg/kg i.v.).
Cardiac output, measured at the peak of the increase in systemic arterial pressure in response to Ang II (1 µg/kg i.v.), was unchanged or increased slightly, whereas calculated total peripheral resistance was increased significantly ( Table 1 ). The increase in total peripheral resistance in response to Ang II was not changed following administration of PD 123319 (10 mg/kg i.v.) (Table 1) , phentolamine (200 µg/kg i.v.), or propranolol (500 µg/kg i.v.), but blunted significantly by administration of candesartan (100 µg/kg i.v.). The increase in total peripheral resistance in response to Ang II was not altered following administration of the candesartan vehicle (1 N Na 2 CO 3 diluted 10:1 in 0.9% NaCl) in a volume of 0.25 ml/kg i.v. Baseline values for systemic arterial pressure, heart rate, cardiac output, and total peripheral resistance did not change significantly after administration of candesartan (20, 40 , or 100 µg/kg i.v.) (data not shown).
Discussion
The results of the present investigation showing that increases in systemic arterial pressure and total peripheral resistance in response to Ang II injections in CD1 mice are antagonised by candesartan, but not by PD 123319, and that the inhibitory effects of candesartan were selective, are consistent with the hypothesis that acute pressor responses to angiotensin are mediated by activation of AT 1 -receptors. [10] [11] [12] [13] [14] In contrast to candesartan, the AT 2 -receptor antagonist PD 123319, at doses of up to 25 mg/kg i.v., had no significant effect on increases in systemic arterial pressure in response to Ang II, suggesting that pressor responses in mice are not mediated or modulated by the actions of the peptide on the AT 1 -receptor and are consistent with previous results. [11] [12] [13] [14] 16, 17 The results of the present study, based on the use of an AT 2 -receptor antagonist, are not consistent with the results of studies in genetically-altered mice in which the AT 1 -receptor is either deficient or is overexpressed in the heart. [7] [8] [9] The reason for these differences and for differences in the studies of Scheuer and Perrone 18 are not clear at the present time. The results of experiments in the AT 2 -receptor knockout mouse suggest that AT 1 -and AT 2 -receptors mediate mutually-counteracting blood pressure responses to Ang II. 8, 9 However, in the present study, systemic arterial pressure was not increased after administration of PD 123319 at doses of 10-25 mg/kg i.v. In addition, the AT 2 -receptor antagonist did not enhance pressor responses to Ang II in control or enalaprilat-treated mice. Moreover, in experiments with the AT 1 -receptor antagonist, candesartan, pressor responses to Ang II were reduced at the lowest dose of the antagonist studied and were abolished following treatment with the highest dose. Although pressor responses to Ang II were abolished, a depressor response to Ang II was not demonstrated. The present results with larger doses of candesartan are consistent with results in the AT 1A -AT 1B -receptor double-knockout mouse, in which pressor responses to Ang II were abolished and a depressor response was not observed. 19 The effects of candesartan and of PD 123319 were similar in control mice and in mice pretreated with the angiotensin-converting enzyme inhibitor (ACE-I) enalaprilat, to inhibit endogenous Ang II production. In enalaprilat-treated animals, pressor responses to Ang II were inhibited and depressor responses to bradykinin were enhanced. In animals pretreated with enalaprilat, candesartan, at a dose of 100 µg/kg i.v., completely blocked pressor responses to Ang II,though PD 123319, at a dose of 25 mg/kg i.v., had no significant effect on the pressor response to Ang II in these animals.
In the present experiments in the anaesthetised CD1 mouse, i.v. injection of Ang II caused a small but significant increase in heart rate, which was attenuated by candesartan (which also antagonised the pressor response to the peptide). The increase in heart rate was also antagonised by propranolol. These data suggest that increases in heart rate in response to Ang II are mediated by an adrenergic mechanism, but the heart rate increase does not, in any large measure, contribute to the increase in systemic arterial pressure induced by the peptide. The administration of the muscarinic antagonist, atropine, in a dose of 1 mg/kg i.v. increased baseline heart rate and, perhaps because of this increase, attenuated the increase in heart rate but did not alter the pressor response to Ang II in the mouse. The results with atropine provide additional support for the concept that changes in heart rate play a minor role in mediating the acute arterial pressure increase in response to i.v. injections of Ang II in the anaesthetised CD1 mouse. Moreover, acute increases in systemic arterial pressure in response to Ang II were not altered by phentolamine at a dose that attenuated pressor responses to norepinephrine. These data suggest that increases in alpha-adrenergic receptor activity do not play an important role in mediating acute pressor responses to Ang II in the mouse.
In previous studies, the pressor response to Ang II was shown to be opposed by the baroreceptor reflex and, as a result, after ganglionic blockade the Ang II response is enhanced. 20 Moreover, the Ang II-mediated increase in sympathetic activity may not be revealed unless the baroreceptors are denervated. 20 Therefore, one interpretation of the lack of effect of phentolamine or propranolol is that autonomic blockade may have attenuated the inhibitory effect of the baroreflex while blunting the indirect actions due to sympathoexcitation. 20 The observation that increases in arterial pressure in response to Ang II are enhanced and prolonged by hexamethonium provides support for the concept that the baroreflex is buffering the increase in arterial pressure in response to Ang II in the mouse. The measurement of cardiac output and the calculation of Ang II-induced increases in total peripheral resistance in mice treated with phentolamine or propranolol provide support for the conclusion that the autonomic nervous system is not involved in mediating the acute haemodynamic response to the peptide. The observation that increases in arterial pressure and total peripheral resistance are blocked by candesartan, but are not changed by PD 123319, provides support for the concept that acute vasoconstrictor responses to the peptide are mediated by actions at the AT 1 -receptor, and that acute responses are not counterbalanced by opposing effects on the AT 2 -receptor in anaesthetised mice. 
PAPER
The results of experiments in the mouse with higher doses of candesartan show that pressor responses to Ang II are abolished and that the inhibitory effect is not surmounted when larger doses of the peptide, up to 100 µg/kg i.v., are injected. These data suggest that the inhibitory effect of high-dose candesartan on the pressor response to Ang II is insurmountable and noncompetitive in nature. The mechanism mediating this non-competitive blockade of angiotensininduced pressor responses is uncertain, but a nonspecific inhibitory effect of the AT 1 -receptor antagonist is unlikely, since pressor responses to norepinephrine, vasopressin, and the thromboxane A 2 receptor mimic, U46619, were not altered by candesartan. It is possible that the insurmountable blockade of Ang II pressor responses induced by candesartan may translate into greater antihypertensive efficacy when compared with other AT 1 -receptor antagonists.
